*|MC:SUBJECT|*

 

DISSEMINATED ON BEHALF OF CONEXEU SCIENCES INC.

Dear Investor,

You’ve seen it on celebrities, athletes, politicians — maybe even a few of your friends.

They suddenly take on the sunken, wrinkled appearance of someone ten or twenty years older. Their cheeks hollow out. Their skin looks deflated. Their face seems to collapse inward.

But they haven’t aged.

They’ve just started using a GLP‑1 drug like Ozempic, Wegovy, or Mounjaro… and while they’re losing weight at record speed, they’re also winding up with what many are now calling “Ozempic face.”

And now many are looking for a solution to this emerging issue.

As a result, some individuals affected by Ozempic face are spending significant amounts on treatments such as Botox, fillers, hyaluronic acid, and biostimulators, as they try to get back to looking like themselves.

In fact, according to the Boston Consulting Group the revenue generated for these treatments thanks to GLP-1 side effects will more than double over the next five years to $2 billion.

But here’s the issue… when it comes to Ozempic face, these products — which are often used to address wrinkles — may not offer a long-term solution for everyone.

They may add volume to the skin for a period of time, but they are not designed to rebuild tissue affected by rapid weight loss.

That has created a potentially significant market for new products intended to address Ozempic face.

But here’s what’s most important for you as an investor:, my research has uncovered a little known company with a breakthrough technology that could change everything. 

The company is called Conexeu Sciences (Nasdaq: CNXU), and it has developed a regenerative technology designed to support facial tissue and help address the appearance of Ozempic face.

As word begins to spread about Conexeu’s flagship product, known as CXU™, the company may be positioned to participate in this developing market.

My name is Robert Kiyosaki, author of Rich Dad, Poor Dad. 

In recent years, I’ve devoted myself to helping ordinary investors identify major market trends — before they become obvious to the general public — so they can potentially reap the rewards that come from getting an early jump on those trends.

My analysis shows that treating Ozempic face is rapidly becoming one of those trends… as more and more people jump on the GLP-1 bandwagon, and then find themselves searching for ways to fill out their face.

Conexeu’s technology may be well suited to this task — and appears different from many products currently on the market… providing structural support intended to help users address changes associated with GLP-1-related facial volume loss.

With many people around the world taking GLP-1 drugs, this company and its proposed solution may be worth watching.

To give you the full story, I’ve written a new Special Report with everything you need to know about Conexeu Sciences (Nasdaq: CNXU).

It’s called The Tissue Wall Street Can’t Print, and it reveals all the reasons why I’m so excited about this unique company’s potential, it’s unique technology, and the investment opportunity it could turn out to be.

To get your free, no-obligation copy of this $199.95-value Report, click here, and you can download it immediately.

According to my research and analysis, Conexeu Sciences (Nasdaq: CNXU) could offer investors exposure to an emerging sector focused on helping people address Ozempic face.

I’m already recommending that subscribers to my Kiyosaki Letter take a closer look at the company and undergo their own due diligence process in relation to the company. I recommend you do the same.

Click here now to download your free Special Report.

Regards,

Robert Kiyosaki, Editor
The Kiyosaki Letter

Robert Kiyosaki is not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Conexeu Sciences Inc. has paid Robert Kiyosaki a fee of $125,000 as consideration for marketing services to be provided over a term of 90 days. [Robert Kiyosaki is a non-arm's-length party who owns zero common shares of Conexeu Sciences Inc.] This newsletter is for informational purposes only. This does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it constitute investment, legal, or tax advice. Prospective investors should consult qualified legal, financial, and tax advisors before making any investment decision. The securities issued by the companies we profile should be considered high risk. If you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC and SEDAR+ filings, press releases, and risk disclosures. We also recommend reviewing any applicable prospectus or offering memorandum filed by the company. The information contained in this newsletter was obtained from the company directly, as well as from SEC and SEDAR+ filings, company websites, and other publicly available sources. While we believe such information to be accurate and reliable, we cannot guarantee its accuracy and prospective investors should conduct their own due diligence.

Forward Looking Statements

This newsletter includes certain statements that may be deemed “forward looking statements”. All statements in this newsletter, other than statements of historical facts, that address events or developments that Conexeu Sciences Inc. (the “Company” or “CXU”) expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements include, but are not limited to, statements regarding:  the Company's plans to seek regulatory clearance or approval for its CXU™ product candidates across its target indications, including wound care, dental soft tissue regeneration, veterinary wound care, and medical aesthetics; the Company's anticipated timelines for regulatory submissions, clinical programs, and commercial market entry across its target verticals; the Company's belief that its regulatory strategy will compress timelines and reduce costs relative to alternative regulatory pathways; the Company's expectation that its CXU™ platform is designed to extend across multiple indications from one core formulation; the Company's expectation regarding the manufacturing, storage, and logistical advantages of its product format, including ambient storage capability, point-of-care reconstitution, and global scalability; the Company's beliefs, based on preclinical data, regarding the performance characteristics and clinical potential of its CXU™ product candidates; the Company's expectation regarding its competitive positioning and potential in the medical aesthetics and regenerative medicine markets; and the Company's estimates regarding the size of the total addressable markets across its target verticals.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that could cause actual events or results to differ from those expressed or implied. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others: additional capital requirements; inability to obtain sufficient funding; no history of commercial operations; no operating revenues; global financial conditions; regulatory risks, including the risk that applicable regulatory authorities do not grant clearance or approval for the Company's product candidates on anticipated timelines or at all; risks related to research and development activities and the uncertainty of their outcomes; manufacturing and supply chain risks; intellectual property risks; commodity markets; insured and uninsured risks; health, safety and community relations; environmental risks and hazards; currency rate risk; infrastructure; competitive industry environment; government regulation; management and organizational growth; climate change and climate change regulations; risk of litigation; reliance on key personnel; internal controls; conflicts of interest; interest rate risk; credit risk; liquidity risk; risks related to commercialization of the Company's products, including market acceptance, pricing, and reimbursement risks; competition from existing and new market entrants; and uninsurable risks.

Preclinical Status

The CXU™ device candidate is investigational. Statements regarding its mechanism, performance, or potential are based on preclinical findings; clinical significance has not yet been established. The Company has applied to pursue FDA clearance through the 510(k) pathway as a Class II device. There can be no assurance that the Company will obtain clearance on its anticipated timeline, or at all.
© 2006 The Investment Journal, All rights reserved.


Our mailing address is:
The Investment Journal
1313 4th Ave N,
Nashville, TN, 37208

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
 
 

Notice: Please understand that by opting out from future emails from this advertiser, you are transferring or
authorizing the transfer of your email address to the advertiser listed above. Zacks has no control over how
your email address is used by the advertiser or other third parties. Accordingly, Zacks disclaims all
responsibility and liability arising from the subsequent use of your email address that is made possible by
your submission of your email address above. You are receiving this email from Zacks Investment Research
because you chose to receive messages from Zacks’ partners on the Zacks web site(s). Please note that
Zacks does not produce or endorse this product, and assumes no responsibility for the use thereof.

Your privacy is important to us. Click here to see our Privacy Policy: https://www.zacks.com/privacy.php
If you do not wish to receive further email solicitations from Zacks on behalf of its partners, please click here
to unsubscribe.

Zacks Investment Research
10 S. Riverside Plaza, Suite 1600
Chicago, IL 60606